| Literature DB >> 28337151 |
Bryna C R Chrismas1, Lee Taylor2, Jason C Siegler3, Adrian W Midgley4.
Abstract
Purpose: To examine whether exercise induced muscle damage (EIMD) and muscle soreness reduce treadmill maximal incremental exercise (MIE) test duration, and true maximal physiological performance as a consequence of exercise induced pain (EIP) and perceived effort.Entities:
Keywords: exhaustion; fatigue; maximum voluntary contraction; muscle soreness; perception of effort
Year: 2017 PMID: 28337151 PMCID: PMC5343012 DOI: 10.3389/fphys.2017.00135
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1Experimental schematic. Measurements were obtained in the sequence listed for the control (CON) and experimental (EXP) groups. ROM, range of motion; CMJ, countermovement jump; SJ, squat jump; MVC, maximum voluntary contraction; VA, voluntary activation; MIE, maximal incremental exercise; DHR, downhill run; Vmax, maximal treadmill velocity.
Values obtained during visit 2 (pre 1) and visit 3 (pre 2) for the indirect markers of EIMD tests and the MIE tests completed for CON and EXP (.
| 1.8 | 1.2 | 0–4 | 2.0 | 1.2 | 0–4 | 0.2 | −0.02, 0.4 | 0.6 | 0.07 | |
| TTE (s) | 998 | 86 | 798–1210 | 1000 | 92 | 784–1229 | 2 | −2.5, 5.4 | 14.0 | 0.48 |
| Soreness (mm) | 11 | 12 | 0–38 | 10 | 11 | 0–34 | −1 | −2.6, 0.9 | 6.0 | 0.35 |
| CK (IU/L) | 109.8 | 40.4 | 42.6–283.0 | 108.7 | 42.7 | 41.3–210.0 | −1.0 | −7.9, 10.0 | 31.6 | 0.82 |
| MVC dom (N.m) | 158.9 | 49.5 | 72.6–254.7 | 155.1 | 47.3 | 62.8–253.0 | −3.7 | −9.3, 1.9 | 18.2 | 0.19 |
| MVC non-dom (N.m) | 148.7 | 46.3 | 64.5–226.6 | 147.4 | 46.0 | 58.4–226.9 | −1.3 | −6.8, 4.1 | 17.8 | 0.62 |
| VA dom (%) | 83 | 10 | 67–97 | 86 | 8 | 68–96 | 3 | −0.3, 5.4 | 9.2 | 0.07 |
| VA non-dom (%) | 83 | 11 | 66–97 | 84 | 9 | 63–96 | 1 | −1.8, 4.3 | 10.0 | 0.42 |
| 3.09 | 0.71 | 1.76–4.21 | 3.13 | 0.72 | 1.78–4.20 | 0.04 | −0.04, 0.1 | 0.24 | 0.30 | |
| 3.60 | 0.87 | 2.02–4.85 | 3.64 | 0.82 | 1.53–5.33 | 0.04 | −0.06, 0.15 | 0.3 | 0.43 | |
| VEmax (L·min−1) | 112 | 27 | 61–165 | 113 | 25 | 64–157 | 0 | −2.5, 3.1 | 9.0 | 0.85 |
| VT (km·h−1) | 11.1 | 1.5 | 7.3–14.3 | 11.2 | 1.6 | 7.0–14.5 | 0.1 | −0.1, 0.4 | 0.86 | 0.32 |
| HRmax (b·min−1) | 196 | 9 | 176–218 | 195 | 9 | 171–216 | −1 | −1.5, 0.3 | 3.0 | 0.21 |
| BLamax (mmol/L) | 11.4 | 2.8 | 5.5–16.0 | 11.3 | 2.9 | 5.5–16.0 | −0.1 | −0.3, 0.2 | 0.9 | 0.67 |
| RERmax | 1.17 | 0.07 | 1.01–1.34 | 1.17 | 0.06 | 1.01–1.31 | 0.01 | −0.02, 0.02 | 0.1 | 0.94 |
| RPEmax | 19 | 2 | 17–20 | 19 | 2 | 17–20 | 0 | −0.2, 0.2 | 0.5 | 0.89 |
Any discrepancies between the mean diff and means is due to rounding error; EIMD, exercise induced muscle damage; MIE, maximal incremental exercise; CON, control; EXP, experimental; SD, between subject standard deviation; mean diff, mean difference; 95% CI, lower and upper bounds of the 95% confidence interval for the mean difference; S.
Reproducibility statistics for the indirect markers of EIMD and the MIE outcomes (.
| EIPmax | 23.3 | 0.82 |
| TTE (s) | 1.9 | 0.98 |
| Soreness (mm) | 8.0 | 0.89 |
| CK (IU/L) | 20.0 | 0.90 |
| MVC dom (N.m) | 8.2 | 0.93 |
| MVC non-dom (N.m) | 8.5 | 0.93 |
| VA dom (%) | 7.7 | 0.79 |
| VA non-dom (%) | 8.5 | 0.82 |
| 5.5 | 0.94 | |
| 6.2 | 0.93 | |
| VEmax (L·min−1) | 5.4 | 0.95 |
| VT (km·h−1) | 3.8 | 0.85 |
| HRmax (b·min−1) | 1.1 | 0.94 |
| BLamax (mmol/L) | 5.6 | 0.95 |
| RERmax | 3.6 | 0.78 |
| RPEmax | 4.9 | 0.88 |
EIMD, exercise induced muscle damage; MIE, maximal incremental exercise; CV, coefficient of variation for repeated measures; ICC, intraclass correlation coefficient (two-way random model for a single rater); range ICC's = 0.78–0.98. See footnotes of Table .
Values obtained during visit 3 (pre 2) and visit 6 (48 h post) for the indirect markers of EIMD tests and the MIE tests completed for CON and EXP (.
| EIPmax [median,(min – max)] | 2 (0–3) | 1 (0–3) | 0 | −1.3, 0.8 | 2 (0–4) | 4 (0–7) | 2 | 1.4, 2.5 |
| TTE (s) | 997 (90) | 1003 (83) | 6 | −18.4, 31.4 | 997 (94) | 964 (98) | −34 | −45.2, −19.7 |
| Soreness (mm) | 8 (5) | 11 (14) | 3 | −18, 10 | 11 (12) | 62 (21) | 51 | 44, 58 |
| CK (IU/L) | 112 (44) | 116 (109) | 4 | −132, 142 | 116 (80) | 227 (131) | 111 | 42, 179 |
| MVC dom (N.m) | 158 (68) | 157 (60) | −1 | −9, 11 | 156 (42) | 142 (49) | −14 | −19, −9 |
| MVC non−dom (N.m) | 153 (62) | 145 (59) | −8 | −19, 3 | 145 (42) | 131 (44) | −14 | −19, −8 |
| VA dom (%) | 85 (9) | 86 (8) | 1 | −8, 5 | 86 (8) | 81 (13) | −5 | −8, −2 |
| VA non-dom (%) | 88 (7) | 86 (8) | −2 | −6, 8 | 83 (9) | 78 (11) | −5 | −9, −2 |
| 3.20 (0.84) | 3.07 (0.77) | −0.13 | −0.41, 0.16 | 3.08 (0.74) | 3.00 (0.77) | −0.09 | −0.21, 0.04 | |
| 3.73 (0.98) | 3.82 (0.98) | 0.09 | −0.31, 0.48 | 3.53 (0.57) | 3.43 (0.54) | −0.09 | −0.89, 0.10 | |
| 120 (34) | 118 (35) | −2 | −13.5, 8.4 | 107 (24) | 108 (25) | 1 | −6.0, 4.7 | |
| VT (km·h·−1) | 11.1 (1.0) | 10.9 (0.8) | −0.2 | −2.2, 1.7 | 11.2 (1.7) | 11.0 (1.5) | −0.2 | −1.1, 0.7 |
| HRmax (b·min−1) | 194 (7) | 194 (7) | 0 | −4.2, 4.7 | 195 (9) | 190 (11) | −5 | −6.8, −2.4 |
| BLamax (mmol/L) | 12.3 (3.2) | 12.2 (3.5) | −0.1 | −1.5, 1.3 | 10.5 (2.9) | 9.6 (2.7) | −0.9 | −1.6, −0.2 |
| RERmax | 1.17 (0.06) | 1.21(0.07) | 0.04 | −0.01, 0.08 | 1.16 (0.07) | 1.16 (0.08) | 0 | −0.03, 0.02 |
| RPEmax [median,(min – max)] | 19 (17–20) | 19 (17–19) | 0 | −0.3, 0.2 | 19 (17–20) | 19 (17–20) | 0 | −0.1, 0.3 |
Values are reported as mean (SD) unless otherwise specified.
significant interaction effect (group x trial). MIE, maximal incremental exercise; EIMD, exercise induced muscle damage; CON, control; EXP, experimental. See footnote of Table .
Relationship between TTE, EIP, MVC, VA, and soreness during visit 6 (48 h post) analyzed using Pearson's r (.
| TTE |
See footnote of Table 1 for definitions of the abbreviations;
statistically significant relationship.